0
Catégories
Documents disponibles dans cette catégorie (12)
Ajouter le résultat dans votre panier Affiner la recherche
Titre : E-cigarettes and smoking cessation in real-world and clinical settings : a systematic review and meta-analysis Type de document : document électronique Auteurs : Sara Kalkhoran, Auteur ; Stanton A. Glantz, Auteur Editeur : Lancet Année de publication : 2016 Collection : The Lancet Respiratory Medicine, ISSN 2213-2600 num. 4(2) Importance : p.116-128 Langues : Anglais (eng) Catégories : [TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] étude:méta-analyse
[TABAC] sevrage tabagiqueIndex. décimale : TA 6.2.3.2 Autres produits En ligne : https://doi.org/10.1016/s2213-2600(15)00521-4 Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9428 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Effect of smoke-free workplaces on smoking behaviour: systematic review / Caroline Fichtenberg (2002)
Titre : Effect of smoke-free workplaces on smoking behaviour: systematic review Type de document : texte imprimé Auteurs : Caroline Fichtenberg, Auteur ; Stanton A. Glantz, Auteur Editeur : BMJ Publishing Group Année de publication : 2002 Collection : British Medical Journal num. 325:188 Importance : 7 p. Langues : Anglais (eng) Catégories : [TABAC] économie du tabac:industrie:cigarettier
[TABAC] étude:méta-analyse
[TABAC] législation:milieu réglementé:lieu de travail
[TABAC] prévention:environnement sans fumée
[TABAC] tabagisme:aspect économique:coût du tabagisme:coût pour la sociétéIndex. décimale : TA 7.8 Lieux non-fumeurs Résumé : Objective: To quantify the effects of smoke-free workplaces on smoking in employees and compare these effects to those achieved through tax increases.
Design: Systematic review with a random effects meta-analysis.
Study selection: 26 studies on the effects of smoke-free workplaces
Setting: Workplaces in the United States, Australia, Canada, and Germany
Participants: Employees in unrestricted and totally smoke-free workplaces
Main outcome measures: Daily cigarette consumption (per smoker and per employee) and smoking prevalence
Results: Totally smoke-free workplaces are associated with reductions in prevalence of smoking of 3.8% (95% confidence interval 2.8% to 4.7%) and 3.1 (2.4 to 3.8) fewer cigarettes smoked per day per continuing smoker. Combination of the effects of reduced prevalence and lower consumption per continuing smoker yields a mean reduction of 1.3 cigarettes per day per employee, which corresponds to a relative reduction of 29%. To achieve similar reductions the tax on a pack of cigarettes would have to increase from $0.76 to $3.05 (€0.78 to €3.14) in the United States and from £3.44 to £6.59 (€5.32 to €10.20) in the United Kingdom. If all workplacesbecame smoke-free, consumption per capita in the entire population would drop by 4.5% in the United States and 7.6% in the United Kingdom, costing the tobacco industry $1.7 billion and £310 million annually in lost sales. To achieve similar reductions tax per pack would have to increase to $1.11 and £4.26
Conclusions: Smoke-free workplaces not only protect non-smokers from the dangers of passive smoking, they also encourage smokers to quit or to reduce consumptionEn ligne : https://www.bmj.com/content/325/7357/188.long Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8111 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effectiveness of smoking cessation therapies : a systematic review and meta-analysis Type de document : texte imprimé Auteurs : Ping Wu, Auteur ; Kumanan Wilson, Auteur ; Popey Dimoulas, Auteur Editeur : BioMed Central Année de publication : 2006 Collection : BMC Public Health num. Vol. 6 Importance : 16 p. Présentation : tab., ill. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : BACKGROUND:
Smoking remains the leading preventable cause of premature deaths. Several pharmacological interventions now exist to aid smokers in cessation. These include Nicotine Replacement Therapy [NRT], bupropion, and varenicline. We aimed to assess their relative efficacy in smoking cessation by conducting a systematic review and meta-analysis.
METHODS:
We searched 10 electronic medical databases (inception to Sept. 2006) and bibliographies of published reviews. We selected randomized controlled trials [RCTs] evaluating interventions for smoking cessation at 1 year, through chemical confirmation. Our primary endpoint was smoking cessation at 1 year. Secondary endpoints included short-term smoking cessation (approximately 3 months) and adverse events. We conducted random-effects meta-analysis and meta-regression. We compared treatment effects across interventions using head-to-head trials and when these did not exist, we calculated indirect comparisons.
RESULTS:
We identified 70 trials of NRT versus control at 1 year, Odds Ratio [OR] 1.71, 95% Confidence Interval [CI], 1.55-1.88, P =< 0.0001). This was consistent when examining all placebo-controlled trials (49 RCTs, OR 1.78, 95% CI, 1.60-1.99), NRT gum (OR 1.60, 95% CI, 1.37-1.86) or patch (OR 1.63, 95% CI, 1.41-1.89). NRT also reduced smoking at 3 months (OR 1.98, 95% CI, 1.77-2.21). Bupropion trials were superior to controls at 1 year (12 RCTs, OR1.56, 95% CI, 1.10-2.21, P = 0.01) and at 3 months (OR 2.13, 95% CI, 1.72-2.64). Two RCTs evaluated the superiority of bupropion versus NRT at 1 year (OR 1.14, 95% CI, 0.20-6.42). Varenicline was superior to placebo at 1 year (4 RCTs, OR 2.96, 95% CI, 2.12-4.12, P =< 0.0001) and also at approximately 3 months (OR 3.75, 95% CI, 2.65-5.30). Three RCTs evaluated the effectiveness of varenicline versus bupropion at 1 year (OR 1.58, 95% CI, 1.22-2.05) and at approximately 3 months (OR 1.61, 95% CI, 1.16-2.21). Using indirect comparisons, varenicline was superior to NRT when compared to placebo controls (OR 1.66, 95% CI 1.17-2.36, P = 0.004) or to all controls at 1 year (OR 1.73, 95% CI 1.22-2.45, P = 0.001). This was also the case for 3-month data. Adverse events were not systematically different across studies.
CONCLUSION:
NRT, bupropion and varenicline all provide therapeutic effects in assisting with smoking cessation. Direct and indirect comparisons identify a hierarchy of effectiveness.En ligne : https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-6-300 Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7965 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Electronic cigarette use and smoking cessation in cohort studies and randomized trials / Linnea Hedman (2021)
Titre : Electronic cigarette use and smoking cessation in cohort studies and randomized trials : a systematic review and metaanalysis Type de document : document électronique Auteurs : Linnea Hedman, Auteur ; Maria Rosaria Galanti, Auteur ; Lotta Ryk, Auteur ; Hans Gilljam, Auteur ; Louise Adermark, Auteur Editeur : European Network for Smoking and Tobacco Prevention (ENSP) Année de publication : 2021 Collection : Tobacco Prevention & Cessation, ISSN 2459-3087 num. 7:62 Importance : 16 p. Présentation : ill. ; tab. ; graph. Langues : Anglais (eng) Catégories : [TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] étude:méta-analyse
[TABAC] sevrage tabagiqueIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : L'objectif de cette méta-analyse était d'évaluer l'association entre l'utilisation de l'e-cigarette et le sevrage tabagique ultérieur dans des études de cohorte et des essais contrôlés randomisés (ECR ou RCT).
En ligne : https://doi.org/10.18332/tpc/142320 Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9439 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Interventions comportementales dans le sevrage tabagique : synthèse et méta‐analyse en réseau Titre original : Behavioural interventions for smoking cessation: an overview and network meta‐analysis Type de document : document électronique Auteurs : Jamie Hartmann-Boyce, Auteur ; Jonathan Livingstone-Banks, Auteur ; José Ordóñez-Mena, Auteur Editeur : The Cochrane Collaboration Année de publication : 2021 Collection : Cochrane Database of Systematic Reviews num. 1 Importance : 52 p. Présentation : ill. ; tab. ; graph. Langues : Français (fre) Langues originales : Anglais (eng) Catégories : [TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:effet du sevrage
[TABAC] sevrage tabagique:efficacité du sevrage
[TABAC] tabagisme:aspect psychologique:comportementIndex. décimale : TA 6 Sevrage tabagique Résumé : Le tabagisme est l'une des principales causes de maladie et de décès dans le monde. Chez les fumeurs, l'arrêt du tabac peut inverser une grande partie des dommages. De nombreuses personnes ont recours à des interventions comportementales pour les aider à arrêter de fumer ; ces interventions peuvent varier considérablement dans leur contenu et leur efficacité. En ligne : https://doi.org/10.1002/14651858.CD013229.pub2 Format de la ressource électronique : Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9915 Est accompagné deAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Pharmacological interventions for smoking cessation : an overview and network meta-analysis (review) Type de document : texte imprimé Auteurs : Kate Cahill, Auteur ; S. Stevens, Auteur ; T. Lancaster, Auteur ; R. Perera, Auteur Editeur : The Cochrane Collaboration Année de publication : 2013 Collection : Cochrane Database of Systematic Reviews num. issue 5 Importance : 49 p. Langues : Français (fre) Catégories : [TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologiqueIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : Abstract
Background
Smoking is the leading preventable cause of illness and premature death worldwide. Some medications have been proven to help people to quit, with three licensed for this purpose in Europe and the USA: nicotine replacement therapy (NRT), bupropion, and varenicline. Cytisine (a treatment pharmacologically similar to varenicline) is also licensed for use in Russia and some of the former socialist economy countries. Other therapies, including nortriptyline, have also been tested for effectiveness.
Objectives
How do NRT, bupropion and varenicline compare with placebo and with each other in achieving long-term abstinence (six months or longer)?
How do the remaining treatments compare with placebo in achieving long-term abstinence?
How do the risks of adverse and serious adverse events (SAEs) compare between the treatments, and are there instances where the harms may outweigh the benefits?
Methods
The overview is restricted to Cochrane reviews, all of which include randomised trials. Participants are usually adult smokers, but we exclude reviews of smoking cessation for pregnant women and in particular disease groups or specific settings. We cover nicotine replacement therapy (NRT), antidepressants (bupropion and nortriptyline), nicotine receptor partial agonists (varenicline and cytisine), anxiolytics, selective type 1 cannabinoid receptor antagonists (rimonabant), clonidine, lobeline, dianicline, mecamylamine, Nicobrevin, opioid antagonists, nicotine vaccines, and silver acetate. Our outcome for benefit is continuous or prolonged abstinence at least six months from the start of treatment. Our outcome for harms is the incidence of serious adverse events associated with each of the treatments.
We searched the Cochrane Database of Systematic Reviews (CDSR) in The Cochrane Library, for any reviews with 'smoking' in the title, abstract or keyword fields. The last search was conducted in November 2012. We assessed methodological quality using a revised version of the AMSTAR scale. For NRT, bupropion and varenicline we conducted network meta-analyses, comparing each with the others and with placebo for benefit, and varenicline and bupropion for risks of serious adverse events.
Main results
We identified 12 treatment-specific reviews. The analyses covered 267 studies, involving 101,804 participants. Both NRT and bupropion were superior to placebo (odds ratios (OR) 1.84; 95% credible interval (CredI) 1.71 to 1.99, and 1.82; 95% CredI 1.60 to 2.06 respectively). Varenicline increased the odds of quitting compared with placebo (OR 2.88; 95% CredI 2.40 to 3.47). Head-to-head comparisons between bupropion and NRT showed equal efficacy (OR 0.99; 95% CredI 0.86 to 1.13). Varenicline was superior to single forms of NRT (OR 1.57; 95% CredI 1.29 to 1.91), and to bupropion (OR 1.59; 95% CredI 1.29 to 1.96).
Varenicline was more effective than nicotine patch (OR 1.51; 95% CredI 1.22 to 1.87), than nicotine gum (OR 1.72; 95% CredI 1.38 to 2.13), and than 'other' NRT (inhaler, spray, tablets, lozenges; OR 1.42; 95% CredI 1.12 to 1.79), but was not more effective than combination NRT (OR 1.06; 95% CredI 0.75 to 1.48). Combination NRT also outperformed single formulations. The four categories of NRT performed similarly against each other, apart from 'other' NRT, which was marginally more effective than NRT gum (OR 1.21; 95% CredI 1.01 to 1.46).
Cytisine (a nicotine receptor partial agonist) returned positive findings (risk ratio (RR) 3.98; 95% CI 2.01 to 7.87), without significant adverse events or SAEs.
Across the 82 included and excluded bupropion trials, our estimate of six seizures in the bupropion arms versus none in the placebo arms was lower than the expected rate (1:1000), at about 1:1500. SAE meta-analysis of the bupropion studies demonstrated no excess of neuropsychiatric (RR 0.88; 95% CI 0.31 to 2.50) or cardiovascular events (RR 0.77; 95% CI 0.37 to 1.59). SAE meta-analysis of 14 varenicline trials found no difference between the varenicline and placebo arms (RR 1.06; 95% CI 0.72 to 1.55), and subgroup analyses detected no significant excess of neuropsychiatric events (RR 0.53; 95% CI 0.17 to 1.67), or of cardiac events (RR 1.26; 95% CI 0.62 to 2.56).
Nortriptyline increased the chances of quitting (RR 2.03; 95% CI 1.48 to 2.78). Neither nortriptyline nor bupropion were shown to enhance the effect of NRT compared with NRT alone. Clonidine increased the chances of quitting (RR 1.63; 95% CI 1.22 to 2.18), but this was offset by a dose-dependent rise in adverse events. Mecamylamine in combination with NRT may increase the chances of quitting, but the current evidence is inconclusive. Other treatments failed to demonstrate a benefit compared with placebo. Nicotine vaccines are not yet licensed for use as an aid to smoking cessation or relapse prevention. Nicobrevin's UK license is now revoked, and the manufacturers of rimonabant, taranabant and dianicline are no longer supporting the development or testing of these treatments.
Authors' conclusions
NRT, bupropion, varenicline and cytisine have been shown to improve the chances of quitting. Combination NRT and varenicline are equally effective as quitting aids. Nortriptyline also improves the chances of quitting. On current evidence, none of the treatments appear to have an incidence of adverse events that would mitigate their use.
Further research is warranted into the safety of varenicline and into cytisine's potential as an effective and affordable treatment, but not into the efficacy and safety of NRT.En ligne : https://doi.org/10.1002/14651858.CD009329.pub2 Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7444 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Risk of serious adverse cardiovascular events associated with varenicline : a systematic review and meta-analysis Type de document : texte imprimé Auteurs : Sonal Singh, Auteur ; Yoon K. Loke, Auteur ; John G. Spangler, Auteur ; Curt D. Furberg, Auteur Année de publication : 2011 Importance : 8 p. Langues : Anglais (eng) Catégories : [DIVERS] anatomie:corps humain:appareil circulatoire:cœur
[TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:effet secondaire
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.2 Autres produits Résumé : CONTEXTE:
Des événements cardiovasculaires indésirables associés à l'utilisation de la varénicline, un médicament anti-tabac largement utilisé, ont été rapportés après la commercialisation. Nous avons effectué une revue systématique et une méta-analyse d'essais contrôlés randomisés pour déterminer les effets cardiovasculaires indésirables graves de la varénicline par rapport au placebo chez les consommateurs de tabac.
MÉTHODES:
Nous avons cherché dans MEDLINE, EMBASE, la base de données de revues systématiques Cochrane, les sites Web d'autorités de réglementation et les registres d'essais cliniques, sans restriction de date ou de langue, jusqu'en septembre 2010 (mise à jour en mars 2011) pour les études publiées et non publiées. Nous avons sélectionné des essais contrôlés randomisés en double aveugle d'une durée d'au moins une semaine impliquant des fumeurs ou des personnes ayant consommé du tabac sans fumée et rapportant des événements cardiovasculaires (ischémie, arythmie, insuffisance cardiaque congestive, mort subite ou décès d'origine cardiovasculaire) comme événements indésirables graves associés à l'utilisation de la varénicline.
RÉSULTATS:
Nous avons analysé les données de 14 essais contrôlés randomisés à double insu portant sur 8 216 participants. Les essais ont duré de 7 à 52 semaines. La varénicline était associée à un risque significativement accru d'événements cardiovasculaires indésirables graves par rapport au placebo (1,06% [52/4908] dans le groupe varénicline vs 0,82% [27/3308] dans le groupe placebo; rapport de cotes de Peto [OR] 1,72, 95% intervalle de confiance [IC] 1,09-2,71; I (2) = 0%). Les résultats de diverses analyses de sensibilité concordaient avec ceux de l'analyse principale et un graphique en entonnoir n'a révélé aucun biais de publication. Il y avait trop peu de décès pour permettre des comparaisons significatives de la mortalité.
INTERPRÉTATION:
Notre méta-analyse soulève des préoccupations en matière de sécurité quant à la possibilité d'un risque accru d'événements cardiovasculaires indésirables graves associés à l'utilisation de varénicline chez les consommateurs de tabac.En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168618/ Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8830 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Smoking cessation and short- and longer-term mortality Type de document : document électronique Auteurs : Eo Rin Cho, Auteur ; Ilene K. Brill, Auteur ; Inger T Gram, Auteur ; Patrick E Brown, Auteur ; Jha Prabhat, Auteur Année de publication : 2024 Importance : 3 p. Langues : Anglais (eng) Catégories : [TABAC] étude:méta-analyse
[TABAC] étude:statistique:mortalité
[TABAC] sevrage tabagiqueIndex. décimale : TA 3.2.1 Mortalité Résumé : BACKGROUND
Smoking cessation reduces mortality and morbidity. However, the extent and rapidity at which cessation reduces contemporary death rates from smoking-related illnesses remain uncertain.
METHODS
We pooled current or former versus never cigarette smoker hazard ratios from four national cohorts with linkage to death registries in the United States, United Kingdom, Norway, and
Canada among adults 20 to 79 years of age from 1974 to 2018. We calculated excess risk differences and survival, comparing current or never smokers with age-specific cessation and
cessation fewer than 3, 3 to 9, or 10 or more years earlier.
RESULTS
Among 1.48 million adults followed for 15 years, 122,697 deaths occurred. Adjusting for age, education, alcohol use, and obesity, current smokers had higher hazard ratios for death
compared with never smokersEn ligne : https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300272 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10222 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Smoking cessation interventions for patients with depression : a systematic review and meta-analysis Type de document : texte imprimé Auteurs : Jennifer M. Gierisch, Auteur ; Lori A. Bastian, Auteur ; Patrick S. Calhoun, Auteur ; Jennifer R. McDuffie, Auteur Editeur : Society of General Internal Medicine Année de publication : 2011 Collection : Journal of general internal Medicine num. 27:3 Importance : p. 351-360 Présentation : tab., graph. Langues : Anglais (eng) Catégories : [TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:méthode de sevrage
[TABAC] tabagisme:effet du tabac:effet psychiatrique:dépressionIndex. décimale : TA 6.2 Méthodes individuelles Résumé : BJECTIVES:
We conducted a systematic literature review of smoking cessation interventions for patients with histories of depressive disorders or current significant depressive symptoms. We examined the comparative effectiveness of smoking cessation strategies on abstinence rates, differential effects of cessation strategies by depression status (i.e., history positive vs. current depression), and differential effects by gender.
DATA SOURCES:
Peer-reviewed literature in MEDLINE, Embase, PsycINFO, and Cochrane Library.
STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, AND INTERVENTIONS:
Randomized controlled trials or secondary analysis of RCT data comparing two or more smoking cessation interventions or intervention to control, and reporting cessation outcomes in adults with depression.
STUDY APPRAISAL AND SYNTHESIS METHODS:
Two trained researchers screened articles for inclusion. When possible, we estimated pooled risk ratios with 95% confidence intervals by using a random effects model with the Mantel-Haenszel method. We synthesized other studies qualitatively. We classified each intervention as antidepressants, nicotine replacement therapy (NRT), brief smoking cessation counseling, smoking cessation behavioral counseling, or behavioral mood management.
RESULTS:
We identified 16 unique RCTs, of which, only three trials recruited participants with current depression. Meta-analysis demonstrated a small, positive effect of adding behavioral mood management (RR = 1.41, 95% CI 1.01-1.96). All included antidepressant trials showed small, positive effects, but risk ratio summary was not significant (RR = 1.31, 95% CI 0.73-2.34). Three NRT trials demonstrated small, positive effects on smoking cessation rates. We found insufficient evidence to examine gender and depression status moderator effects.
LIMITATIONS:
Few RCTs exist that test smoking cessation interventions among adults with depression. To make meaningful comparisons, we created broad intervention categories that contained heterogeneity.
CONCLUSIONS AND IMPLICATIONS OF KEY FINDINGS:
Few trials enrolled smokers with current depression. Most of data identified were from subgroup analyses of patients history-positive for depression. However, several promising interventions exist. Healthcare providers should consider encouraging their patients with significant depressive symptoms or depression histories to seek smoking cessation services that include NRT and behavioral mood management.Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8092 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : A systematic review and meta‑analysis of the association between e‑cigarette use among non‑tobacco users and initiating smoking of combustible cigarettes Type de document : document électronique Auteurs : Mimi M. Kim, Auteur ; Isabella Steffensen, Auteur ; Red Thaddeus D. Miguel, Auteur Editeur : Melbourne School of Population and Global Health Euan Lawson Année de publication : 2024 Collection : Harm Reduction Journal Importance : 33 p. Présentation : ill., tab., graph. Langues : Anglais (eng) Catégories : [TABAC] CANDIDATS:e-cigarette
[TABAC] étude
[TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:aide au sevrageIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : Introduction
The rapid increase in e-cigarette use over the past decade has triggered an important public health question on the potential association between e-cigarette use and combustible cigarette smoking. Following AMSTAR 2 and PRISMA guidelines, this evidence synthesis sought to identify and characterize any associations
between e-cigarette use among individuals not smoking cigarettes and initiation of cigarette smoking. Methods The protocol was registered on September 24, 2018 (PROSPERO 2018 CRD42018108540). Three databases were queried from January 01, 2007 to April 26, 2023. Search results were screened using the PICOS review method.
Results
Among 55 included studies (40 “good” and 15 “fair”; evidence grade: “high”) that adjusted for gender, age, and race/ethnicity between groups, generally, there was a significant association between non-regular e-cigarette use and initiation of cigarette smoking, further supported by the meta-analytic results (AOR 3.71; 95% CI 2.86–4.81). However, smoking initiation was most often measured as ever/current cigarette smoking. Two studies (quality: 2 “good”) evaluated progression to regular cigarette smoking among individuals with regular use of e-cigarettes, and generally found no significant associations. One study (“good”) evaluated smoking initiation among individuals with regular use of e-cigarettes, finding an increasing probability of ever smoking cigarettes with increased e-cigarette use. Twelve
studies (10 “good” and two “fair”) examining progression to regular smoking among individuals with non-regular use of e-cigarettes reported inconsistent findings.
Conclusions
Numerous methodological flaws in the body of literature limit the generalizability of these results to all individuals who are not smoking cigarettes with few studies measuring established/regular use/smoking of e-cigarettes and cigarettes. Further, studies did not control adequately for specific confounding variables representing common liabilities between e-cigarette use and cigarette smoking, nor did they account for sufficient follow-up durations. Collectively, these flaws limit the generalizability of findings to the question of an association between e-cigarette use
and cigarette smoking initiation.En ligne : https://doi.org/10.1186/s12954-024-01013-x Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10302 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : The effectiveness and applicability of motivational interviewing : a practice-friendly review of four meta-analyses Type de document : document électronique Auteurs : Brad Lundahl, Auteur ; Brian L. Burke, Auteur Editeur : Wiley Année de publication : 2009 Collection : Journal of Clinical Psychology, ISSN 1097-4679 num. 65(11) Importance : 14 p. Note générale : Disponible sur http://www.antoniocasella.eu/archila/lundahl_2009.pdf Langues : Anglais (eng) Catégories : [TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche psychologique:entretien motivationnelIndex. décimale : TA 6.2.2 Approche psychologique (y compris entretien motivationnel) Résumé :
This article reviews the research support for Motivational interviewing (MI) so that practitioners can make informed decisions about the value and applicability of MI in their clinical work. We highlight the evidence from the three published meta-analyses of MI and a recent meta-analysis that we completed. MI is significantly (10%-20%) more effective than no treatment and generally equal to other viable treatments for a wide variety of problems ranging from substance use (alcohol, marijuana, tobacco, and other drugs) to reducing risky behaviors and increasing client engagement in treatment. Although most client-related variables are unrelated to outcomes (e.g., age, gender, severity), some decisions about treatment format (e.g., individual vs. group) are important. For example, relying solely on group-delivered MI appears to be less effective than one-on-one MI, whereas delivering MI with problem feedback is likely to generate better outcomes for some problems than MI alone.
En ligne : https://doi.org/10.1002/jclp.20638 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10005 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : The efficacy of smoking cessation therapies in cardiac patients : a meta-analysis of randomized controlled trials Type de document : texte imprimé Auteurs : M.J. Eisenberg, Auteur ; Lisa M. Blum, Auteur ; Kristian B. Filion, Auteur ; Stephane Rinfret, Auteur Editeur : Oakville [Canada] : Canadian Cardiology Publications Inc. Année de publication : 2010 Collection : The Canadian journal of cardiology, ISSN 0828-282X num. 26:2 Importance : p. 73-79 Présentation : tab., graph. Langues : Anglais (eng) Catégories : [TABAC] étude:méta-analyse
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche psychologique:thérapie cognitivo-comportementaleIndex. décimale : TA 6.1 Généralités Résumé : Abstract
INTRODUCTION:
Several meta-analyses have examined the efficacy of smoking cessation therapies in the general population. However, little is known about the efficacy of these therapies in cardiac patients. Therefore, a meta-analysis of randomized controlled trials (RCTs) was performed to determine the efficacy of behavioural therapy and pharmacotherapy for smoking cessation in cardiac patients.
METHODS:
The medical literature was systematically reviewed to identify smoking cessation RCTs in cardiac patients. Only RCTs that reported smoking abstinence at six or 12 months were included. Smoking abstinence was examined based on the 'most rigorous criterion', defined as the most conservative outcome reported in any given RCT.
RESULTS:
Eleven behavioural therapy RCTs that enrolled 2105 patients and four pharmacotherapy RCTs that enrolled 1542 patients were identified. RCTs differed in the type of behavioural therapy administered as well as the total length and duration of the intervention. RCTs differed in the type of pharmacotherapy administered (one nicotine patch RCT, one nicotine gum RCT and two bupropion RCTs). Behavioural therapy was associated with a significantly higher proportion of smoking abstinence than usual care (OR 1.97 [95% CI 1.37 to 2.85]). Pharmacotherapies were more efficacious than placebo (pooled OR 1.72 [95% CI 1.15 to 2.57]).
CONCLUSIONS:
Both behavioural therapy and pharmacotherapy are more efficacious than usual care for smoking cessation in cardiac patients. The present meta-analysis highlights the need for head-to-head RCTs to identify which smoking cessation therapy is preferred in cardiac patients as well as RCTs examining the efficacy of combined behavioural and pharmacotherapies.En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851386/ Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8100 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
